Cargando…
Evolution of Public Health Human Papillomavirus Immunization Programs in Canada
Background: Since 2007, all Canadian provinces and territories have had a publicly funded program for vaccination against human papillomavirus (HPV) infection. The objective of this study was to describe the evolution of these vaccination programs. Methods: This was a targeted literature review of p...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985769/ https://www.ncbi.nlm.nih.gov/pubmed/33617515 http://dx.doi.org/10.3390/curroncol28010097 |
_version_ | 1783668318380490752 |
---|---|
author | Goyette, Alexandra Yen, Glorian P. Racovitan, Voica Bhangu, Parambir Kothari, Smita Franco, Eduardo L. |
author_facet | Goyette, Alexandra Yen, Glorian P. Racovitan, Voica Bhangu, Parambir Kothari, Smita Franco, Eduardo L. |
author_sort | Goyette, Alexandra |
collection | PubMed |
description | Background: Since 2007, all Canadian provinces and territories have had a publicly funded program for vaccination against human papillomavirus (HPV) infection. The objective of this study was to describe the evolution of these vaccination programs. Methods: This was a targeted literature review of public HPV vaccination programs and vaccination coverage rates, based on information provided by jurisdictional public health authorities. Results: HPV vaccination of schoolgirls began in school years 2007/08 to 2010/11 with three doses of the quadrivalent HPV vaccine in all provinces except Quebec, which started with two doses. By 2018/19, all jurisdictions were vaccinating with two doses of the nonavalent vaccine in both girls and boys, except Quebec, which used a mixed vaccination schedule with one dose of the nonavalent and one dose of the bivalent vaccines. Public HPV vaccination programs in most provinces include after-school catch-up vaccination. Immunocompromised or other high-risk individuals are eligible for the HPV public vaccination program in most provinces, but policies vary by jurisdiction. In 2017/18, vaccination coverage rates in provincial HPV school-based programs varied from 62% in Ontario to 86% in Prince Edward Island in girls and from 58% in Ontario to 86% in Prince Edward Island in boys. Conclusions: Since their introduction, Canadian school-based HPV public vaccination programs have evolved from a three-dose to a two-dose schedule, from a quadrivalent to a nonavalent vaccine, and from a girls-only to a gender-neutral policy. Vaccination coverage rates have varied markedly and only Prince Edward Island and Newfoundland/Labrador have maintained rates exceeding 80%. |
format | Online Article Text |
id | pubmed-7985769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79857692021-03-24 Evolution of Public Health Human Papillomavirus Immunization Programs in Canada Goyette, Alexandra Yen, Glorian P. Racovitan, Voica Bhangu, Parambir Kothari, Smita Franco, Eduardo L. Curr Oncol Article Background: Since 2007, all Canadian provinces and territories have had a publicly funded program for vaccination against human papillomavirus (HPV) infection. The objective of this study was to describe the evolution of these vaccination programs. Methods: This was a targeted literature review of public HPV vaccination programs and vaccination coverage rates, based on information provided by jurisdictional public health authorities. Results: HPV vaccination of schoolgirls began in school years 2007/08 to 2010/11 with three doses of the quadrivalent HPV vaccine in all provinces except Quebec, which started with two doses. By 2018/19, all jurisdictions were vaccinating with two doses of the nonavalent vaccine in both girls and boys, except Quebec, which used a mixed vaccination schedule with one dose of the nonavalent and one dose of the bivalent vaccines. Public HPV vaccination programs in most provinces include after-school catch-up vaccination. Immunocompromised or other high-risk individuals are eligible for the HPV public vaccination program in most provinces, but policies vary by jurisdiction. In 2017/18, vaccination coverage rates in provincial HPV school-based programs varied from 62% in Ontario to 86% in Prince Edward Island in girls and from 58% in Ontario to 86% in Prince Edward Island in boys. Conclusions: Since their introduction, Canadian school-based HPV public vaccination programs have evolved from a three-dose to a two-dose schedule, from a quadrivalent to a nonavalent vaccine, and from a girls-only to a gender-neutral policy. Vaccination coverage rates have varied markedly and only Prince Edward Island and Newfoundland/Labrador have maintained rates exceeding 80%. MDPI 2021-02-22 /pmc/articles/PMC7985769/ /pubmed/33617515 http://dx.doi.org/10.3390/curroncol28010097 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Goyette, Alexandra Yen, Glorian P. Racovitan, Voica Bhangu, Parambir Kothari, Smita Franco, Eduardo L. Evolution of Public Health Human Papillomavirus Immunization Programs in Canada |
title | Evolution of Public Health Human Papillomavirus Immunization Programs in Canada |
title_full | Evolution of Public Health Human Papillomavirus Immunization Programs in Canada |
title_fullStr | Evolution of Public Health Human Papillomavirus Immunization Programs in Canada |
title_full_unstemmed | Evolution of Public Health Human Papillomavirus Immunization Programs in Canada |
title_short | Evolution of Public Health Human Papillomavirus Immunization Programs in Canada |
title_sort | evolution of public health human papillomavirus immunization programs in canada |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985769/ https://www.ncbi.nlm.nih.gov/pubmed/33617515 http://dx.doi.org/10.3390/curroncol28010097 |
work_keys_str_mv | AT goyettealexandra evolutionofpublichealthhumanpapillomavirusimmunizationprogramsincanada AT yenglorianp evolutionofpublichealthhumanpapillomavirusimmunizationprogramsincanada AT racovitanvoica evolutionofpublichealthhumanpapillomavirusimmunizationprogramsincanada AT bhanguparambir evolutionofpublichealthhumanpapillomavirusimmunizationprogramsincanada AT kotharismita evolutionofpublichealthhumanpapillomavirusimmunizationprogramsincanada AT francoeduardol evolutionofpublichealthhumanpapillomavirusimmunizationprogramsincanada |